tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2022 Sep 27;9(10)
fac499.
doi: 10.1093/ofid/ofac499. eCollection 2022 Oct.
Successful Treatment of Delayed Localized Necrotizing Inflammatory Myositis After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine: A Case Report
Jennifer Chen Li[SUP] 1 2 [/SUP], Jonathan Siglin[SUP] 2 3 [/SUP], Michael S Marshall[SUP] 2 4 [/SUP], Anat Stemmer-Rachamimov[SUP] 2 4 [/SUP], Seth M Bloom[SUP] 2 5 6 [/SUP], Kimberly G Blumenthal[SUP] 1 2 7 [/SUP]
Affiliations
Abstract
Reported adverse reactions to the mRNA-1273 vaccine (Spikevax, Moderna Inc) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) range from mild, local delayed cutaneous reactions to rarer, more serious reactions such as myocarditis. Here, we describe the presentation and successful treatment of delayed, localized necrotizing inflammatory myositis following a third dose of the mRNA-1273 SARS-CoV-2 vaccine. To our knowledge, this is the first report of biopsy-confirmed, delayed inflammatory myositis after administration of an mRNA-1273 SARS-CoV-2 vaccine booster.
Keywords: COVID-19; SARS-CoV-2; mRNA vaccine; myositis.
. 2022 Sep 27;9(10)
fac499.doi: 10.1093/ofid/ofac499. eCollection 2022 Oct.
Successful Treatment of Delayed Localized Necrotizing Inflammatory Myositis After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine: A Case Report
Jennifer Chen Li[SUP] 1 2 [/SUP], Jonathan Siglin[SUP] 2 3 [/SUP], Michael S Marshall[SUP] 2 4 [/SUP], Anat Stemmer-Rachamimov[SUP] 2 4 [/SUP], Seth M Bloom[SUP] 2 5 6 [/SUP], Kimberly G Blumenthal[SUP] 1 2 7 [/SUP]
Affiliations
- PMID: 36267257
- PMCID: PMC9578160
- DOI: 10.1093/ofid/ofac499
Abstract
Reported adverse reactions to the mRNA-1273 vaccine (Spikevax, Moderna Inc) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) range from mild, local delayed cutaneous reactions to rarer, more serious reactions such as myocarditis. Here, we describe the presentation and successful treatment of delayed, localized necrotizing inflammatory myositis following a third dose of the mRNA-1273 SARS-CoV-2 vaccine. To our knowledge, this is the first report of biopsy-confirmed, delayed inflammatory myositis after administration of an mRNA-1273 SARS-CoV-2 vaccine booster.
Keywords: COVID-19; SARS-CoV-2; mRNA vaccine; myositis.